Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
**Background:** Despite the availability of new treatments, multiple myeloma (MM) is an incurable cancer with nearly all patients relapsing and undergoing multiple lines of treatment. Performing head-to-head comparisons of all treatment options is not feasible. Thus, network meta-analyses play an im...
Saved in:
Main Authors: | Michael Dolph, Gabriel Tremblay, Adrienne M Gilligan, Hoyee Leong |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2021-08-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/001c.27080 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
by: Yin-Che Wang, et al.
Published: (2025-12-01) -
Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study
by: Juan M. Cano-Calderón, et al.
Published: (2025-01-01) -
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
by: Luciano J. Costa, et al.
Published: (2025-02-01) -
Patient Preference for Once-Weekly Dosing in Type 2 Diabetes Mellitus in Japan
by: Rohini Sen, et al.
Published: (2016-03-01) -
Nontuberculous mycobacterial infections following teclistamab in multiple myeloma
by: Matthew Ho, et al.
Published: (2025-02-01)